HANA LEZAMA: Open Payments
NPI 1871143495 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,953 in 174 payments from 19 companies in 2025. Trend: 2023 $2,668 · 2024 $3,339 · 2025 $4,953
Food & beverage: $4,763Education: $190
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $887 |
| Janssen Biotech, Inc. | 18 | $792 |
| Galderma Laboratories, L.P. | 11 | $556 |
| Lilly USA, LLC | 16 | $411 |
| Novartis Pharmaceuticals Corporation | 13 | $395 |
| LEO Pharma Inc. | 20 | $361 |
| Regeneron Healthcare Solutions, Inc. | 11 | $335 |
| Organon LLC | 4 | $280 |
| UCB, Inc. | 14 | $268 |
| GENZYME CORPORATION | 5 | $159 |
Products named: TREMFYA, SKYRIZI, DUPIXENT, TALTZ, NEMLUVIO, ANZUPGO, RINVOQ, Bimzelx.
Industry payments across NY — which companies pay providers there.
